糖尿病视网膜病变中的甲福明:机制,治疗潜力和障碍
Hamza Alasbily1, Fardous Ali Fahmi2, Majdi Abdulhamid Abdala3
1Faculty of Dentistry, Department of Basic Medical Science, University of Benghazi, Benghazi, LBY.
Cureus
|August 7, 2025
概括
甲胺通过向关键疾病机制,有望减缓糖尿病视网膜病变 (DR) 的进展. 然而,需要进一步的大规模研究来确认其安全性和有效性,特别是在患有脏问题的患者中.
科学领域:
- 眼科医生 眼科 眼科
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病视网膜病变 (DR) 管理旨在预防视力丧失,但早期治疗效果较差.
- 甲福明是一种常见的抗糖尿病药物,通过影响氧化应激,血管新生和炎症来表现出对DR的管理潜力.
研究的目的:
- 审查在糖尿病视网膜病变中甲福明治疗效果的机制.
- 讨论现有的临床证据和美特福林用于DR治疗的局限性.
主要方法:
- 关于甲福明和糖尿病视网膜病变的临床前和临床研究的文献综述.
- 分析甲福明对DR病理途径的影响.
主要成果:
- 甲福明会影响关键的DR机制,如氧化应激,血管生成和炎症.
- 临床前和临床研究表明,甲福林可以减少DR的发展和进展.
结论:
- 甲胺为糖尿病视网膜病变提供了潜在的治疗选择.
- 副作用,功能障碍的安全性,以及需要进行大规模试验是目前的限制.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
298
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
298
Diabetes: Management and Pharmacotherapy
386
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
386
Dipeptidyl Peptidase 4 Inhibitors
260
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
260
Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
262
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
262
Diabetes: Symptoms, Diagnosis, and Complications
694
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
694


